DENDREON PHARMACEUTICALS, LLC

Lobbying for DENDREON PHARMACEUTICALS, LLC

Filing 1st Quarter - Report

1st Quarter (Jan 1 - Mar 31) 2025 · California · House · Senate · $60,147.00 expenses · posted May 6, 2025

Lobbying activity 1

Medical/Disease Research/Clinical Labs

Access to autologous cellular immunotherapies in Medicare Part B. Implementation of provisions included in Subtitle B of PL.117-169-Inflation Reduction Act of 2022.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.